Drug cocktails for effective treatment of glioblastoma multiforme
Author:
- Waldemar DebinskiWDWaldemar Debinski
- 1 April 2008
- journal article
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 8 (4) , 515-517
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Interleukin-13 Receptor α2, EphA2, and Fos-Related Antigen 1 as Molecular Denominators of High-Grade Astrocytomas and Specific Targets for Combinatorial TherapyClinical Cancer Research, 2008
- A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor–expressing tumor cellsMolecular Cancer Therapeutics, 2007
- Direct Intracerebral Delivery of Cintredekin Besudotox (IL13-PE38QQR) in Recurrent Malignant Glioma: A Report by the Cintredekin Besudotox Intraparenchymal Study GroupJournal of Clinical Oncology, 2007
- Antigenic Profiling of Glioma Cells to Generate Allogeneic Vaccines or Dendritic Cell–Based TherapeuticsClinical Cancer Research, 2007
- AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma PatientsCancer Cell, 2007
- A Genome-Wide Screen Reveals Functional Gene Clusters in the Cancer Genome and Identifies EphA2 as a Mitogen in GlioblastomaCancer Research, 2006
- Using molecular information to guide brain tumor therapyNature Clinical Practice Neurology, 2006
- EphA2 as a Novel Molecular Marker and Target in Glioblastoma MultiformeMolecular Cancer Research, 2005
- Personalized, Multivalent, and More Affordable: The Globalization of VaccinesClinical Cancer Research, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005